Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03160898 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 458
- Enrollment target
NCT03160898 is a Phase 2 study that has completed, run by Cytokinetics. The registered enrollment target is 458 participants.
The verdict
NCT03160898, a Phase 2 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 458 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS.
Interventions
- DRUG Placebo
- DRUG Reldesemtiv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2017-07-24 |
| Est. Completion | 2019-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03160898
The ClinicalTrials.gov registry entry for NCT03160898 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 458 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03160898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03160898 about?
NCT03160898 is a clinical study titled "A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)". The purpose of this study was to assess the effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS.
What is the current status of trial NCT03160898?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 458 participants. The study started on 2017-07-24. Estimated completion is 2019-03-07.
What interventions are being tested in trial NCT03160898?
The interventions under investigation include: Placebo (DRUG), Reldesemtiv (DRUG).
Who is sponsoring clinical trial NCT03160898?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.